Image

North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market – Industry Trends and Forecast to 2030

Healthcare

Image

North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Published Report
  • May 2023
  • North America
  • 350 Pages
  • No of Tables: 30
  • No of Figures: 39

North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2023–2030
Diagram Market Size (Base Year) USD MILLION
Diagram Market Size (Forecast Year) USD 6,797.66
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, By Diagnosis (Imaging Tests and Pancreatic Function Test), Treatment  (Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Drug Type (Generic and Branded), End User (Hospitals, Specialty Clinics, Homecare,  Diagnostic Centers, Research and Academic Institute, and Others), Distribution Channel (Direct Tender, Retail Pharmacy, Third Party Distributors, and Others) - Industry Trends and Forecast to 2030.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market

North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Analysis and Insights

The increasing awareness of advanced diagnostic technology North America has enhanced the demand for the market. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved advancement of processes and techniques also contributes to the rising demand for exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics MarketExocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market

The North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in the developmental activity for launching novel services in the market. The increasing development in advanced healthcare techniques is further boosting the market growth. However, difficulties such as the stringent regulations to hamper the exocrine pancreatic insufficiency (EPI) therapeutic and diagnostic sector, the side effects and religious hurdles associated with pancreatic enzyme replacement therapy (PERT) might hamper the growth of the North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the forecast period.

Increasing healthcare expenditure on advancement and development is expected to give opportunities to the market. However, the high cost associated with EPI diagnosis and treatment may challenge the market growth.

Data Bridge Market Research analyzes that the North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to reach the value of USD 6,797.66 million by 2030, at a CAGR of 7.3% during the forecast period.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in Million, Volumes in Units, and Pricing in USD

Segments Covered

Diagnosis (Imaging Tests and Pancreatic Function Test), Treatment  (Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Drug Type (Generic and Branded), End User (Hospitals, Specialty Clinics, Homecare,  Diagnostic Centers, Research and Academic Institute, and Others), Distribution Channel (Direct Tender, Retail Pharmacy, Third Party Distributors, and Others)

Countries Covered

U.S., Canada, and Mexico

Market Players Covered

EagleBio, AbbVie., Nordmark Arzneimittel GmbH & Co., Digestive Care, Inc., Cilian AG, Alcresta Therapeutics, Inc., ChiRhoClin, Abbott, Bioserv Diagnostics, Laboratory Corporation of America, Organon group of companies Metagenics LLC, Janssen, Nestlé., VIVUS LLC., and ScheBo Biotech AG among others

Market Definition

Exocrine pancreatic insufficiency (EPI) is a medical condition where the pancreas fails to produce enough digestive enzymes to digest fats, proteins, and carbohydrates in the intestine. EPI can be caused by various conditions, such as chronic pancreatitis, cystic fibrosis, and pancreatic cancer. Therapeutics for EPI involve using pancreatic enzyme replacement therapy (PERT), which provides the necessary digestive enzymes that the pancreas is not producing. PERT is usually taken with meals and snacks to help break down food and absorb nutrients properly; several PERT products are available, such as pancrelipase, pancreatin, and lipase.

Diagnostics for EPI may involve blood tests to measure the levels of digestive enzymes in the blood, fecal elastase test to check the level of pancreatic elastase in the stool, and imaging tests, such as CT scans, MRI, or endoscopic ultrasound to visualize the pancreas and detect any abnormalities. Additionally, breath tests can measure the levels of hydrogen and methane in the breath, indicating EPI. 

North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:     

Drivers

  • Increasing prevalence of exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis and cystic fibrosis

Exocrine pancreatic insufficiency (EPI) is a condition caused when the pancreas fails to make sufficient amounts of digestive enzymes to help digestion and absorption of nutrients. Chronic pancreatitis is the main cause of EPI in adults. Pancreatitis causes inflammation and swelling of the pancreas. Over time, it can damage the pancreatic cells that make digestive enzymes. Similarly, cystic fibrosis is one of the main causes of EPI in children. It is inherited from parents and causes thick mucus to build up in the lungs, creating difficulty breathing. Mucus also accumulates in the pancreas and prevents digestive enzymes from reaching the small intestine. People with EPI can’t absorb enough fats, proteins, and carbohydrates from foods which is called malabsorption.

Therefore, the increasing prevalence of EPI due to chronic pancreatitis and cystic fibrosis is driving the growth of the market in the forecast period.

  •   Rising technological advancements in the diagnosis and treatment of EPI

There is a lack of consensus regarding the best diagnostic approach, and experts have noted the non-reliability and non-specificity of available diagnostic tests. Available diagnostic tests for EPI include fecal fat quantification, the fecal elastase-1 test, and the C-mixed triglyceride breath test. Developing a machine learning model that identifies patients in a commercial medical claims database who likely have EPI but are undiagnosed is one of the recent objectives to advance the diagnosis and treatment framework of EPI.

Therefore, the rising technological advancements in the diagnosis and treatment of EPI is driving the market's growth in the forecast period.

Restraint

  • Stringent regulations to hamper the exocrine pancreatic insufficiency (EPI) therapeutic and diagnostic sector

The use of therapies and medications for EPI disorders across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases which are preventable by early diagnosis. At the same time, the players of the EPI disorders products manufacturers in the market must follow certain regulations to get approval from the upper authorities for launching the product in the market. These stringent guidelines need to be followed and this is one of the most difficult tasks of all the steps. The U.S. Food and Drug Administration (FDA) regulates the U.S. and the European Union (EU) regulates Europe. However, the rapid development of privacy policies and regulations is being made in the Asia-Pacific and EMEA, including India, Russia, China, South Korea, Singapore, Hong Kong, and Australia. Some drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), have instructed that manufacturers obtain regulatory approvals before marketing their products because of possible adverse effects and inadequate effectiveness. These stringent FDA regulations have made approval of pancrelipase products difficult.

Hence, from the above instances, concluded that stringent regulations may restrain the growth of the exocrine therapeutic insufficiency therapeutics and diagnostics market in the forecast period.

Opportunity

  • Increasing prevalence of pancreatic disorders and associated condition

EPI is a prominent side effect of pancreatic diseases like cancer, cystic fibrosis, and chronic pancreatitis. These ailments can harm the pancreas, impairing its capacity to generate digestive enzymes and result in EPI. The rising prevalence of pancreatic diseases and related ailments worldwide is driving the demand for EPI therapies and diagnostics. These conditions can cause damage to the pancreas, leading to a reduced ability to produce digestive enzymes, which can result in EPI. Cystic fibrosis's damage to the pancreas makes it another disorder that can result in EPI. The genetic disease known as cystic fibrosis impacts the reproductive, digestive, and respiratory systems. Cystic fibrosis is more common in Caucasians, particularly those with a Northern European ancestry, than worldwide. As the incidence of these conditions continues to increase, the demand for EPI therapeutics and diagnostics is also expected to grow. This presents a significant opportunity for pharmaceutical companies and manufacturers to develop new and effective treatments and diagnostic tests for EPI.

Thus, the increasing prevalence of pancreatic disorders and associated conditions is expected to act as an opportunity for market growth.

Challenge

  • High cost associated with EPI diagnosis and treatment

The complexity of the illness and the requirement for specialized tests make the diagnosis of EPI expensive. Faecal elastase testing, secretin-stimulated pancreatic function testing, and imaging tests like magnetic resonance imaging (MRI) and endoscopic ultrasonography (EUS) are the most frequently used diagnostic procedures for EPI. These tests can be pricey, and not all medical professionals can access the tools and training needed to carry them out.  The high expense of identifying EPI can also delay a diagnosis, which can exacerbate symptoms and raise healthcare costs over time. Untreated EPI can cause continuing digestive problems, nutrient malabsorption, and weight loss in patients, all of which can increase medical expenses and difficulties.

Thus, the high cost associated with EPI diagnosis and treatment is expected to act as a challenge in the market growth.

Recent Developments

  • In August 2021, AzurRx announced that it had engaged in the development of yeast-derived lipase, MS1819, which has been engineered to have superior enzymatic activity as compared to current treatments.
  • In February 2023, Codexis, Inc. and Nestlé Health Science announced the interim findings from a Phase 1 trial examining the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108. A lipase variation called CDX-7108 was created expressly to get around the drawbacks of the current pancreatic enzyme replacement treatment (PERT). This has aided the business in marketing the product.

North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Scope

The North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is categorized into five notable segments such as diagnosis, treatment, drug type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.   

Diagnosis

  • Imaging Tests
  • Pancreatic Function Test

On the basis of diagnosis, the North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into imaging test and pancreatic function test.

Treatment

  • Nutritional Management
  • Pancreatic Enzyme Replacement Therapy (PERT)

On the basis of treatment, the North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into nutritional management and pancreatic enzyme replacement therapy (PERT).

Drug Type

  • Generic
  • Branded

On the basis of drug type, the North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into generic and branded.

End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Diagnostic Centre
  • Research and Academic Institutes
  • Others

On the basis of end user, the North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into Hospitals, Specialty Clinics, Homecare, Diagnostic Centers, Research and Academic Institute, and others.

Distribution Channel

  • Direct Tender
  • Retail Pharmacy 
  • Third-Party Distributor
  • Others

On the basis of distribution channel, the North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into direct tender, retail pharmacy, third party distributor, and others.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market

North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Regional Analysis/Insights

The North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is categorized into five notable segments such as diagnosis, treatment, drug type, end user, and distribution channel.   

The countries covered in this market report are the U.S., Canada, and Mexico.

The U.S. is dominating due to the presence of key market players in the largest consumer market with high GDP.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share Analysis

The North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the North America nurse call systems market.

Some of the major players operating in the North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are EagleBio, AbbVie. Nordmark Arzneimittel GmbH & Co., Digestive Care, Inc., Cilian AG, Alcresta Therapeutics, Inc., ChiRhoClin, Abbott, Bioserv Diagnostics, Laboratory Corporation of America, Organon group of companies Metagenics LLC, Janssen, Nestlé., VIVUS LLC., and ScheBo Biotech AG, among others.


SKU-

TABLE 1 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 2 NORTH AMERICA PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 NORTH AMERICA PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ENZYME, 2021-2030 (USD MILLION)

TABLE 4 NORTH AMERICA PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA ORAL IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 6 NORTH AMERICA NUTRITIONAL MANAGEMENT IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA NUTRITIONAL MANAGEMENT IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 8 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA PANCREATIC FUNCTION TEST IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA PANCREATIC FUNCTION TEST IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA STOOL IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 12 NORTH AMERICA IMAGING TESTS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA IMAGING TESTS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA BRANDED IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA BRANDED IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA GENERIC IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA HOSPITALS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA HOSPITALS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA SPECIALTY CLINICS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA DIAGNOSTIC CENTER IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA HOMECARE IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA RESRACH AND ACADEMIC INSTITUTES IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA OTHERS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA DIRECT TENDER IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA RETAIL PHARMACY IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA OTHERS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market is projected to grow at a CAGR of 7.3% during the forecast period by 2030.
The future market value of the North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market is expected to reach USD 6,797.66 million by 2030.
The major players in the North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market EagleBio, AbbVie., Nordmark Arzneimittel GmbH & Co., Digestive Care, Inc., Cilian AG, Alcresta Therapeutics, Inc., ChiRhoClin, Abbott, Bioserv Diagnostics, Laboratory Corporation of America, etc.
The countries covered in the North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market are U.S., Canada, and Mexico.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials